Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Peak Plasma Concentration (Cmax) of MVT-2163 alone and in combination with MVT-5873
研究概览
简要总结
Open label, nonrandomized, dose-escalation trial of MVT-2163 and MVT-5873 used in performing PET scans. The study is designed to determine the best time and dose of these agents that result in the best PET image of a tumor. Subjects will be seen on days 1, 2, 4, and 7 for imaging and a clinical assessment. The last study visit is on day 28.
详细描述
This is an open label, nonrandomized, dose-escalation trial of a fixed dose of MVT-2163 and varying antibody masses of MVT-5873. The study is designed to identify an optimal dose (total antibody mass) and optimal timing, for tumor imaging using PET scanning. This trial will include a dose escalation and an expansion phase. During the dose escalation portion of the study, a determination of the optimal time to perform PET imaging will be made. Following the identification of the "optimal" dose and timing, an 10 additional subjects will be imaged using the best dose and timing.
In each portion of the study subjects will have a screening visit and, no more than 28 days later, those who are eligible for the study will receive MVT-2163. Each cohort will have 3-6 subjects. Subjects in cohort 1 will be administered MVT-2163 alone on day 1. Subjects in cohorts 2 and 3 will receive MVT-5873 on day 1, followed approximately 10 minutes later by MVT-2163. Subjects will return for visits to the clinic on days 2, 4, and 7 for additional imaging and safety assessments. A follow-up visit will occur on day 28.
The study will also evaluate the tissue distribution and pharmacokinetics of MVT-2163 and, based on these data, the study will estimate the radiation dosimetry of MVT-2163. Safety assessments will be performed using ECGs, vital signs measurements, assessments of performance status, and clinical laboratory measurements.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed, informed consent
- •Histologically confirmed, locally-advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) or other malignancies known to express CA19-9 positive malignancies
- •At least one lesion by CT or MRI ≥ 2 cm
- •ECOG performance status of 0 to 2
- •Absolute neutrophil count ≥1.50 x 109/L
- •Hemoglobin ≥ 9.0 g/dL (in the absence of red blood cell transfusions in the prior 14 days)
- •Platelet count >75,000/ mm3
- •AST/SGOT, ALT/SGPT ≤2.5 x ULN, unless liver metastases are clearly present, then ≤5.0 x ULN
- •Total bilirubin <1.5x the upper limit of normal unless considered due to Gilbert's syndrome in which case, <3x the upper limit of normal
- •Serum creatinine (serum or plasma) ≤ 1.5 x ULN or GFR>50 mL/min
- •Serum albumin > 3.0g/dL
- •Willingness to participate in collection of pharmacokinetic samples
- •Willingness to use adequate contraception throughout study and for a period of 90 days last dose of study drug
排除标准
- •Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
- •Major surgery other than diagnostic surgery within 28 days
- •History of anaphylactic reaction to human, or humanized, antibody
- •Other on-going cancer therapy or investigational agents (except MVT-5873 )
- •Known history of HIV or Hepatitis C
- •Pregnant or currently breast-feeding
- •Psychiatric illness/social situations that would interfere with compliance with study requirements
- •Significant cardiovascular risk including, but not limited to, recent (within 28 days) coronary stenting or myocardial infarction within 6 months
研究组 & 干预措施
Cohort 1
Subjects receive 3 mg of MVT-2163 without the addition of prior MVT-5873.
干预措施: MVT-2163 (Drug)
Cohort 2
Subjects receive 17 mg of MVT-5873 followed by 3 mg of MVT-2163.
干预措施: MVT-2163 (Drug)
Cohort 2
Subjects receive 17 mg of MVT-5873 followed by 3 mg of MVT-2163.
干预措施: MVT-5873 (Drug)
Cohort 3
Subjects receive 47 mg of MVT-5873 followed by 3 mg of MVT-2163.
干预措施: MVT-2163 (Drug)
Cohort 3
Subjects receive 47 mg of MVT-5873 followed by 3 mg of MVT-2163.
干预措施: MVT-5873 (Drug)
结局指标
主要结局
Peak Plasma Concentration (Cmax) of MVT-2163 alone and in combination with MVT-5873
时间窗: About 12 months
Cmax of MVT-2163
Half-life (T1/2) of MVT-2163 alone and in combination with MVT-5873
时间窗: About 12 months
Half-life (T1/2) of MVT-2163
Safety of MVT-2163 alone and in combination with MVT-5873
时间窗: About 12 months
Number of subjects with treatment-related adverse events as assessed by CTCAE v4.0 will be collected and compiled
Biodistribution of MVT-2163 alone and in combination with MVT-5873
时间窗: About 12 months
The biodistribution of MVT-2163 will be determined by measuring radiation exposure for key organs and tissues
Dose of MVT-5873 required for optimal tumor visualization when combined with a fixed dose of MVT-2163
时间窗: About 12 months
Three doses of MVT-5873 (0, 17, and 47 mg) will be combined with MVT-2163 in order to determine which dose results in the best PET imaging of tumor
Determine the optimal time interval between MVT-2163 dose administration and tumor PET imaging
时间窗: About 12 months
Images will be taken on several days over the first week to determine the optimal day for obtaining PET images
Area under the plasma concentration versus time curve (AUC) of MVT-2163 alone and in combination with MVT-5873
时间窗: About 12 months
AUC of MVT-2163
次要结局
- The ability of MVT-2163 to detect sites of disease (localized and metastatic) in pancreatic cancer and/or other CA19-9 positive malignancies(About 12 months)
- Radiation dosimetry estimates using quantitative MVT-2163 biodistribution uptake data(About 12 months)
- MVT-2163 PET imaging results in comparison with varying levels of CA19-9 antigen expression by IHC(About 12 months)
- MVT-2163 PET imaging results in comparison with circulating CA19-9 levels(About 12 months)
- Presence of anti-drug antibodies (ADA) using an MVT-5873 ADA assay(About 12 months)